Frontlight ResearchEarly access
Not yet taking people in United StatesPhase 1
Lorlatinib Plus TNG462 in ALK+ MTAP Del NSCLC
Key facts
- Who runs it
- Dana-Farber Cancer Institute
- Where
- Boston, United StatesSee the 2 sites
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 1
- People taking part
- 30 people, planned
- Starts
- 30 Apr 2027
- Expected to end
- 30 Jun 2028
- Type of study
- Interventional
- Treatments tested
- TNG462 vopimetostat
- Lorlatinib
- Record updated
- 16 November 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 31 criteriaShow less
Who can take part
- Age ≥ 18 years
- Histologically or cytologically confirmed NSCLC harboring an ALK rearrangement, documented by an FDA/EMA-approved or validated local test
- Confirmed MTAP loss, demonstrated by immunohistochemistry (IHC) as complete loss in the presence of a positive internal control, or homozygous deletion by next-generation sequencing (NGS) in a CLIA-/ISO-accredited laboratory. The Sponsor-Investigator will review molecular testing to confirm eligibility (central reading of the IHC sample and/or repeat MTAP staining on archival tissue; check of the NGS report). Cases with heterogenous MTAP loss in IHC defined as MTAP loss in at least 80% of the tumor cells but less than 100%, may be included with the permission of the Sponsor-Investigator and after central revision of the slides
- Radiographic disease progression after at least one or more ALK TKIs, including prior lorlatinib therapy. Prior chemotherapy and prior neladalkib (NVL-655) are allowed
- At least one measurable extracranial lesion according to RECIST v1.1
- ECOG performance status 0-1 (Appendix A). ECOG performance status 2 may be allowed with the permission of the Sponsor-Investigator
- Adequate organ and marrow function, defined as:; ANC ≥ 1.5 × 10⁹/L; Platelets ≥ 75 × 10⁹/L, without platelet transfusion within 7 days prior to screening hematology assessment; Hemoglobin > 8.5 g/dL without transfusion within 14 days prior to screening hematology assessment; AST/ALT ≤ 2.5 × ULN (≤ 5 × ULN with documented liver metastases); Total bilirubin ≤ 1.5 × ULN; Creatinine clearance ≥ 45 mL/min
- Stable, previously treated brain metastases permitted if neurologically stable ≥ 2 weeks and on ≤ 10 mg prednisone equivalent. Untreated CNS metastases may be permitted with PI approval if: lesions are asymptomatic, ≤5 mm in size, no radiologic evidence of surrounding edema, and no current or anticipated need for corticosteroids
- Life expectancy ≥ 12 weeks
- Ability to swallow oral medication. TNG 462 tablets may be crushed and administered via NG-G tube if necessary, with written approval from Principal Investigator. Lorlatinib may not be crushed
- Written informed consent obtained prior to study procedures
- Participants must understand, sign and date the written informed consent form prior to any protocol-specific procedures performed. Participants should be able and willing to comply with study visits and procedures as per protocol
Who cannot take part
- Leptomeningeal carcinomatosis or spinal cord compression unless treated, clinically stable ≥ 4 weeks, and off steroids ≥ 14 days
- History of myocardial infarction, unstable angina, coronary revascularization, stroke, or transient ischemic attack (TIA) within 6 months before C1D1
- Interstitial lung disease, organizing pneumonia, or drug-induced pneumonitis, including prior lorlatinib-related pneumonitis, unless completely resolved
- Active uncontrolled infection requiring intravenous therapy within 7 days before C1D1
- Any other active malignancy within 2 years prior to enrollment, except adequately treated basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, early-stage prostate cancer undergoing active surveillance, curatively treated thyroid cancer, early stage breast cancer or DCIS, or any in situ cancers that have been treated with curative intent
- Has any of the following: prior history of drug-induced or toxic retinopathy, or optic neuropathy; uncontrolled glaucoma; pre-existing macular degeneration; ongoing Grade ≥3 retinopathy, optic neuropathy, or optic neuritis; or any other known active retinal pathology
- History of seizure disorder requiring enzyme-inducing antiepileptic drugs that cannot be substituted
- Symptomatic congestive heart failure (NYHA ≥ Class II) or uncontrolled hypertension despite optimal medical therapy
- Known HBsAg-positive or HCV RNA-positive infection with detectable viral load. Participant on suppressive antiviral therapy with undetectable viremia are eligible
- HIV infection with CD4 < 200/μL or on antiretrovirals that are strong CYP3A modulators
- Clinically significant gastrointestinal disorder that may affect absorption of oral medications (e.g., malabsorption syndrome, chronic diarrhea, short-bowel syndrome)
- Clinically significant neurocognitive disorder, mood alteration, or psychiatric illness (including major depression or psychosis) that, in the investigator's judgment, could be exacerbated by lorlatinib or impair adherence
- Known hypersensitivity to TNG462, lorlatinib, or any of their excipients
- 3.2.1 Prior treatment with a PRMT5 inhibitor, MAT2A inhibitor, or any investigational agent targeting the same pathway; 3.2.2 Prior treatment with lorlatinib resulting in discontinuation due to ≥ Grade 3 toxicity or with unresolved ≥ Grade 2 neurocognitive, pulmonary, or psychiatric adverse events at screening; 3.2.3 Ongoing or unresolved toxicity > Grade 1 from previous anticancer therapy (per CTCAE v5.0), except for the following: alopecia, endocrinopathies controlled by replacement therapy, or other protocol-allowed persistent Grade 2 toxicities (e.g., neuropathy) that, in the investigator's judgment, do not pose an unacceptable safety risk; 3.2.4 Major surgery within 4 weeks before first dose or incomplete recovery from surgery; 3.2.5 Radiotherapy within 2 weeks before C1D1 (≤ 1 week for palliative RT ≤ 2 Gy/fraction); prior cranial RT permitted if completed ≥ 2 weeks before C1D1 and participant neurologically stable; 3.2.6 Concomitant use of strong or moderate CYP3A inhibitors or inducers, CYP3A or P-gp substrates with a narrow therapeutic index (e.g., digoxin, cyclosporine), or OATP1B3 substrates with a narrow therapeutic index (e.g. rosuvastatin, methotrexate, sirolimus), that cannot be discontinued or replaced; 3.2.7 Use of medications known to prolong QTc > 480 ms that cannot be safely discontinued
- Baseline QTc > 480 ms (Fridericia), PR > 220 ms, clinically significant atrioventricular (AV) block, or uncontrolled arrhythmia
- Uncontrolled hyperlipidemia defined as fasting total cholesterol > 300 mg/dL or triglycerides > 300 mg/dL despite medical management
- Pregnancy or breastfeeding. Women of childbearing potential must have a negative serum pregnancy test within 7 days before first dose and agree to use two highly effective contraceptive methods during treatment and for ≥ 6 months after the last dose. Male participants must use effective contraception for ≥ 3 months after the last dose
- Any condition (medical, psychiatric, social, or laboratory abnormality) that, in the opinion of the investigator, may confound study results, increase risk, or interfere with study compliance
- Participants who, in the investigator's or Sponsor-Investigator's judgment, are unable to comply with protocol requirements or whose participation would not be in their best interest may be excluded
Where in United States
- Brigham and Women's HospitalBoston, United StatesContact: Alice Shaw, MD, PhDNot yet recruiting
- Dana-Farber Cancer InstituteBoston, United StatesContact: Alice Shaw, MD, PhDNot yet recruiting
About the trial
What the trial wants to find out
TAP-ALK is a DF/HCC investigator-sponsored interventional study of TNG462 (vopimetostat) in combination with lorlatinib for participants with MTAP-deleted, ALK-rearranged non-small cell lung cancer (NSCLC) following progression on prior tyrosine kinase inhibitor (TKI) therapy. The study is being conducted under IND 183798 and plans to enroll 30 participants.
The group in the trial
- TNG462 plus LorlatinibTreatment being tested
Participants receive TNG462 once daily and lorlatinib once daily according to the study treatment plan and study calendar.
Treatment: TNG462 vopimetostat and Lorlatinib
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- TAP-ALK: A Phase I/II Study of TNG462 in Combination With Lorlatinib in MTAP-Deleted, ALK-Rearranged NSCLC Following Progression on Prior TKI Therapy
- Record updated
- 16 November 2026